Cumberland Pharmaceuticals Inc
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -10.5% | +298.8% | -25.8% | -93.7% | -14.4% | +2,416.0% | -18.2% | -89.5% | +797.1% | -12.2% | -90.3% | -197.9% | – | -1.8% | +77.2% | +17.1% | +33.3% | -27.9% | -110.0% | – | |
| – | +997.8% | +29.7% | +3.2% | +3.8% | +19.8% | +6.3% | -13.3% | +44.4% | +52.8% | +12.9% | +6.7% | +10.5% | +12.7% | +47.7% | +7.8% | -3.0% | +15.7% | +8.3% | +4.7% | -12.5% | |
| – | – | +187.5% | +32.8% | +52.6% | +13.5% | +13.2% | -18.3% | +6.0% | +12.8% | -18.3% | +36.9% | +74.6% | -8.3% | +8.9% | -29.6% | -29.1% | -39.7% | -18.4% | -17.3% | +35.3% | |
| – | – | – | – | – | – | – | – | – | – | – | +144.5% | +109.4% | -73.9% | -45.3% | +329.2% | -191.6% | – | – | – | – | |
| – | -163.8% | – | -103.2% | – | – | +6,560.9% | +140.8% | -46.7% | +51.6% | -44.7% | -269.3% | – | – | -127.9% | – | +131.5% | +34.1% | -57.8% | -72.1% | +67.3% | |
| – | +1,957.4% | -97.5% | -17.9% | +431.0% | +7.9% | -43.0% | +479.5% | +198.0% | -56.8% | -17.3% | -21.1% | -30.1% | +187.1% | -94.2% | +758.6% | -83.2% | +485.1% | -78.2% | -60.3% | -45.5% | |
| – | +1,957.4% | -97.5% | -17.9% | +431.0% | +7.9% | -43.0% | +4,280.6% | -73.6% | +19.0% | -61.1% | +32.8% | – | -391.5% | – | -176.5% | -71.4% | +2,624.6% | -99.2% | – | -8,236.8% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | +595.5% | -86.1% | -12.4% | +90.4% | -40.6% | -10.1% | +23.7% | -52.8% | +47.8% | -22.7% | +21.4% | -47.0% | -25.1% | -24.1% | -29.7% | -21.8% | -54.5% | |
| – | – | – | – | – | – | – | -78.4% | +772.0% | – | -98.1% | +7,459.5% | +137.5% | +78.9% | -115.2% | +126.1% | – | +0.0% | -384.7% | – | -502.7% | |
| – | +74.8% | -176.4% | +34.4% | – | -118.4% | -71.1% | +17.6% | +117.6% | -81.8% | +212.5% | -77.9% | – | +266.5% | -171.2% | +40.1% | -50.1% | -42.0% | +260.1% | – | -3,525.8% | |
| – | -85.7% | +533.7% | -77.7% | +6,488.2% | -119.2% | – | -445.4% | – | – | – | – | – | -260.3% | – | -1,363.8% | – | -418.4% | – | – | – | |
| – | -309.3% | – | -26.0% | -104.9% | – | – | -44.5% | -248.2% | – | -7.3% | -149.1% | – | – | – | +17.5% | +81.4% | +6.5% | -11.6% | -114.0% | – |
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.